Background: Recent studies have shown that monocytes in human peripheral blood are heterogeneous. The clinical significance of 2 distinct monocyte subsets as a marker of late in-stent restenosis (ISR) following implantation of bare-metal stents (BMSs) in patients with acute myocardial infarction (AMI) was examined.
tent implantation is a standard procedure in percutaneous coronary intervention (PCI). However, the problem of in-stent restenosis (ISR), which is a main limitation of coronary stent implantation, remains unresolved, especially for implantation of bare-metal stents (BMSs) following ST-elevation myocardial infarction (STEMI). 1 Excessive in-stent neointimal hyperplasia is the main contributing factor to ISR. 2, 3 There is increasing evidence from several experimental and clinical studies to indicate that white blood cells, particularly monocytes, play a central role in restenosis after balloon angioplasty and stent implantation. Fukuda et al reported that circulating monocyte levels increased after coronary stent implantation, and the peak monocyte count was related to in-stent neointimal volume in patients who received successful BMS implantation. 4 Recent studies have shown that monocytes in human peripheral blood are heterogeneous. 5-8 Monocytes can be divided into 2 subsets based on the differential expression of CD14 and CD16: CD14 + CD16 -monocytes that express C-C motif chemokine receptor 2 (CCR2) and CD14 + CD16 + monocytes that express C-X3-C motif chemokine receptor 1 (CX3CR1). 5- 8 The role of monocyte subsets in atherogenesis has been investigated in experimental studies in mice and rats; 9 however, as similar studies are not possible in patients, atherogenesis in humans is less well understood. 10 In the present study, we examined the clinical significance of 2 distinct monocyte subsets as a marker of late ISR following BMS implantation in patients with STEMI. In a previous study, 11 we showed that circulating CD14 + CD16 -and CD14 + CD16 + monocytes increased in STEMI patients, peaking on days 3 and 5, respectively, after onset, whereas the 2 distinct monocyte subset counts did not significantly change between 8 and 12 days after STEMI. In this study, we selected 12 days after STEMI onset as the measurement point for monocyte subsets, because this might avoid the influence of myocardial necrosis.
LIU Y et al. Figure 1 . Expression of CX3CR1- and CCR2-positive monocytes. CX3CR1 and CCR2 surface expressions were measured by flow cytometry as described in the Methods section. Numbers of CD14 + CD16 + CX3CR1 + monocytes (A) and CD14 + CD16 -CCR2 + monocytes (B) were determined at 12 days after ST-elevation myocardial infarction (STEMI) onset.
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Methods
Patient Population
Patients with STEMI who was treated successfully with a coronary stent were enrolled in this study. All patients were between 34 and 85 years of age. The criteria for diagnosis of STEMI were: (1) chest pain within 24 h before admission that lasted for more than 30 min and was not relieved by sublingual nitroglycerin; (2) ST-segment elevation on electrocardiogram; and (3) elevated serum creatine kinase levels. Exclusion criteria were: (1) AMI for more than 24 h from onset; (2) a history of renal dysfunction requiring dialysis; (3) evidence of malignant disease; or (4) unwillingness to participate. All patients received coronary angiography on admission and then underwent emergency PCI using coronary stents. Only BMS were used because our hospital does not implant drug-eluting stents for acute coronary syndrome patients. All patients were routinely treated with heparin, isosorbide dinitrate, ticlopidine, aspirin, and an angiotensinconverting enzyme inhibitor or angiotensin II receptor blocker.
Clinical Parameters
Patient age, gender, and coronary risk factors (smoking, hypertension, diabetes mellitus, hyperlipidemia, and obsesity) were recorded. The diagnostic criteria for coronary risk factors were as follows: hypertension, blood pressure ≥140/90 mmHg and/or a history of taking antihypertensive medication; diabetes mellitus, fasting plasma glucose ≥126 mg/dl, casual plasma glucose ≥200 mg/dl, or diabetes pattern in the 75-g oral glucose tolerance test; hyperlipidemia, serum total cholesterol levels >220 mg/dl or serum triglyceride levels >150 mg/dl; obesity, and body mass index ≥25 kg/m 2 .
Coronary Angiography
Coronary angiograms were reviewed separately by 2 independent observers unaware of the clinical data (H.T. and A. K.). Quantitative coronary analysis (QCA) was performed at baseline (immediately after the procedure) and at follow up (9 months later). Proximal and distal vessel diameters, interpolated reference diameter, minimum lumen diameter (MLD), percent diameter stenosis (%DS), and late lumen loss were assessed. ISR was defined as %DS >50% at follow up.
Cytometric Analysis
For cytometric analysis, monoclonal antibodies against CD14 (fluorescein isothiocyanate (FITC) or phycoerythrin (PE), Clone M5E2, BD Bioscience), CD16 (PE-Cy™5, Clone 3G8, BD Bioscience), CCR2 (PE, Catalog Number FAB151P, R&D Systems Inc), and CX3CR1 (FITC, Clone 2A9-1, MBL, Nagoya, Japan) were used. A total of 100 μl of blood was incubated for 15 min at room temperature. For erythrocyte lysis and leukocyte fixation, 1 ml of lysing solution was added (Lysingsolution, Becton Dickinson, Germany). Nonspecific immunoglobulin G isotypes were used as negative controls. Flow cytometry was performed using a FACSCaliber with CellQuest software (Becton Dickinson Bioscience, San Jose, CA, USA). Monocytes were first gated in a forward scatter/sideward scatter dotplot, and then 3-color fluorescence was measured within the monocyte gate. The CD14 + CD16 + monocytes were defined as monocytes expressing CD16 and either high (CD14 bright CD16 + ) or lower levels of CD14 (CD14 dim CD16 + ). Thus, CD14 bright CD16 + and CD14 dim CD16 + were not analyzed separately, according to previous studies. 12 Then, CD14 + CD16 + CX3CR1 + cell numbers were determined ( Figure 1A) . List mode files were collected for 100,000 cells from each sample. Similarly, CD14 + CD16 -CCR2 + monocyte numbers were determined as shown in Figure 1B .
Laboratory Measurements
Serum levels of total cholesterol, low-and high-density lipoprotein (HDL) cholesterol, and triglycerides were measured by using standard methods. High-sensitivity C-reactive protein was analyzed using a commercially available testing kit (NLatex CRP II, Dade Behring Gmbh, Marburg, Germany).
Statistical Analysis
If not stated otherwise, continuous variables were expressed as mean ± SD. Baseline characteristics were analyzed using the χ2 test, Fisher's test, or 1-way ANOVA, as appropriate. When data were not normally distributed (according to the Shapiro-Wilks test), they were expressed as median and range, and analyzed with non-parametric methods. To assess correlations between 2 parameters, simple linear regressions were calculated using the least squares method. Multiple LIU Y et al. 
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regression analysis was performed to predict late lumen loss using variables that could affect restenosis. P<0.05 was considered significant. All statistical analyses were performed with the statistical software package, SPSS 11.0 (SPSS Inc, Chicago, IL, USA).
Results
Patient Characteristics
After 9 months, angiographic restenosis was observed in 18 patients treated with BMS. The clinical characteristics of these patients were compared with 53 patients without restenosis; there were no significant differences in age, sex, coronary risk factors, medications, or peak creatinine kinase levels ( Table 1) . Baseline characteristics were similar between patients treated with BMS who experienced restenosis and those who did not ( Table 1) . Table 2 shows the QCA data for the restenosis and nonrestenosis groups. There were no differences in angiographic or stent implantation procedural characteristics between the 2 groups, except for reperfusion time and maximum balloon pressure. Repeat angiography was performed in all eligible patients. The mean time to angiographic follow up was 9±2 months. All quantitative parameters, including MLD, %DS, and in-stent lumen loss, in patients with or without restenosis are shown in Table 2 . 
Quantitative Coronary Analysis at Follow up
LIU Y et al.
In-Stent Restenosis or Late Lumen Loss and Monocyte Subsets
Although patients with restenosis did not show any significant differences in terms of total monocyte (Figure 2A ) or CD14 + CD16 -CCR2 + monocyte counts ( Figure 2B ), compared to patients without restenosis, they had a significantly higher number of circulating CD14 + CD16 + CX3CR1 + monocytes ( Figure 2C ). Angiographic late lumen loss was significantly correlated with the levels of CD14 + CD16 + CX3CR1 + monocytes, but not with CD14 + CD16 -CCR2 + or total monocytes (Figure 3) . Multiple regression analysis showed that late lumen loss was independently associated with the levels of CD14 + CD16 + CX3CR1 + monocytes alone ( Table 3 ; R=0.48, P<0.001).
Discussion
There is abundant evidence to suggest that monocytes play a role in restenosis following BMS implantation. Given the diversity of circulating monocytes, the exact identity of neointima-associated monocyte subsets deserves careful consideration. The results of this study showed for the first time the positive correlation between circulating CD14 + CD16 + CX3CR1 + monocyte subsets and ISR or late gain loss following BMS implantation. Although BMS implantation is a standard procedure in PCI, the problem of ISR, which is the main limitation of coronary stent implantation, remains unresolved. 1 Excessive in-stent neointimal hyperplasia is the main cause of ISR. 2, 13 Experimental and clinical studies have suggested that inflammation plays an important role in the pathogenesis of intimal hyperplasia after arterial injury. 14, 15 Welt et al have demonstrated in rabbit models of injury that there are differences in the vascular responses to balloon-induced and stent-induced injuries. 16 They showed that balloon injury is associated with early and transient infiltration of neutrophils without monocyte accumulation, whereas stent implantation is associated with an early influx of neutrophils followed by a sustained recruitment of monocytes over days or weeks. 16 Monocytes migrate into the damaged area either as a direct response or through the release of platelet-derived factors. Activated monocytes release large amounts of pro-inflammatory cytokines, which cause vasoconstriction and non-specific recruitment, proliferation, and activation of other cells including vascular smooth muscle cells in the vascular wall. 17 Diversity and plasticity are hallmarks of the monocytemacrophage system. 
Study Limitations
There are some limitations in this study. First, it was conducted at a single center with a small sample size. Larger cohort studies will be necessary to confirm our findings. Second, our study was observational and does not provide a mechanistic explanation for the significant relationship between ISR following BMS implantation and the expression levels of CD14 + CD16 + CX3CR1 + monocytes. Finally, previous studies have reported the importance of circulating CD34-positive bone marrow-derived cells at 7 days after bare-metal stenting in patients with stable coronary artery disease, 26 or polymorphonuclear leukocytes at 2 days after percutaneous transluminal coronary angioplasty (PTCA) in patients with stable angina pectoris. 27 These results suggest that the time points of circulating leukocytes to predict late restenosis following PCI were different from underlying conditions. In this study, we selected 12 days after STEMI onset as the measurement point for monocyte subsets, because this might avoid the influence of myocardial necrosis. 11 Although this study showed that the number of CD14 + CD16 + CX3CR1 + monocytes at 12 days after PCI was the clinical significance as a marker of late ISR in patients with STEMI, another large clinical trial to validate the time point should be considered.
Conclusions
We have demonstrated for the first time that CD14 + CD16 + CX3CR1 + monocytes might be involved in ISR following BMS implantation. The results suggest that coronary neointi- Monocyte Subsets and In-Stent Restenosis mal hyperplasia might be associated with circulating monocyte subets, which could provide new conceptual and therapeutic approaches for treating ISR after BMS implantation. These findings also highlight the importance of characterizing specific functions of monocyte subsets to enable therapeutic intervention.
